{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:55:25Z","timestamp":1787500525963,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["no.81671689"],"award-info":[{"award-number":["no.81671689"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["no.81501477"],"award-info":[{"award-number":["no.81501477"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FDCT grant","award":["FDCT101\/2015\/A3"],"award-info":[{"award-number":["FDCT101\/2015\/A3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to examine the performance of the four risk of malignancy index (RMI) in discriminating borderline ovarian tumors (BOTs) and benign ovarian masses in daily clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 162 women with BOTs and 379 women with benign ovarian tumors diagnosed at the Second Affiliated Hospital of Harbin Medical University from January 2012 to December 2016 were enrolled in this retrospective study. Also, we classified these patients into serous borderline ovarian tumor (SBOT) and mucinous borderline ovarian tumor (MBOT) subgroup. Preoperative ultrasound findings, cancer antigen 125 (CA125) and menopausal status were reviewed. The area under the curve (AUC) of receiver operator characteristic curves (ROC) and performance indices of RMI I, RMI II, RMI III and RMI IV were calculated and compared for discrimination between benign ovarian tumors and BOTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>RMI I had the highest AUC (0.825, 95% CI: 0.790\u20130.856) among the four RMIs in BOTs group. Similar results were found in SBOT (0.839, 95% CI: 0.804\u20130.871) and MBOT (0.791, 95% CI: 0.749\u20130.829) subgroups. RMI I had the highest specificity among the BOTs group (87.6, 95% CI: 83.9\u201390.7%), SBOT (87.6, 95% CI: 83.9\u201390.7%) and MBOT group (87.6, 95% CI: 83.9\u201390.7%). RMI II scored the highest overall in terms of sensitivity among the BOTs group (69.75, 95% CI: 62.1\u201376.7%), SBOT (74.34, 95% CI: 65.3\u201382.1%) and MBOT (59.18, 95% CI: 44.2\u201373.0%) group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared to other RMIs, RMI I was the best-performed method for differentiation of BOTs from benign ovarian tumors. At the same time, RMI I also performed best in the discrimination SBOT from benign ovarian tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-019-0568-3","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T08:02:46Z","timestamp":1568620966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors"],"prefix":"10.1186","volume":"12","author":[{"given":"Shuang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunping","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Fei","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo Tsz On","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"issue":"10","key":"568_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/oxfordjournals.aje.a116428","volume":"136","author":"R Harris","year":"1992","unstructured":"Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative ovarian Cancer group. Am J Epidemiol. 1992;136(10):1204\u201311.","journal-title":"Am J Epidemiol"},{"key":"568_CR2","first-page":"204","volume":"48","author":"H Taylor","year":"1929","unstructured":"Taylor H. Malignant and semi-malignant tumors of the ovary. Surg Gynecol Obstet. 1929;48:204\u201330.","journal-title":"Surg Gynecol Obstet"},{"key":"568_CR3","doi-asserted-by":"crossref","unstructured":"Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand. 1971;50:1):1\u20137.","DOI":"10.3109\/00016347109157278"},{"key":"568_CR4","unstructured":"Serov SF, Scully RE, Sobin LH. Histological typing of ovarian tumors. WHO international histological classification of tumors no.9. World Health Organization: Geneva, Switzerland, 1973;90(9):756\u2013759."},{"issue":"2","key":"568_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejogrb.2009.04.031","volume":"145","author":"MS Lenhard","year":"2009","unstructured":"Lenhard MS, Mitterer S, Kumper C, Stieber P, Mayr D, Ditsch N, et al. Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. Eur J Obstet Gynecol Reprod Biol. 2009;145(2):189\u201394.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"8","key":"568_CR6","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.humpath.2004.03.004","volume":"35","author":"JD Seidman","year":"2004","unstructured":"Seidman JD, Soslow RA, Vang R, Berman JJ, Stoler MH, Sherman ME, et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol. 2004;35(8):918\u201333.","journal-title":"Hum Pathol"},{"issue":"2","key":"568_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00428-016-2040-8","volume":"470","author":"S Hauptmann","year":"2017","unstructured":"Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch. 2017;470(2):125\u201342.","journal-title":"Virchows Arch"},{"issue":"20","key":"568_CR8","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1200\/JCO.2007.10.8076","volume":"25","author":"I Cadron","year":"2007","unstructured":"Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clin Oncol. 2007;25(20):2928\u201337.","journal-title":"J Clin Oncol"},{"issue":"3","key":"568_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1006\/gyno.1998.5076","volume":"70","author":"M Emoto","year":"1998","unstructured":"Emoto M, Udo T, Obama H, Eguchi F, Hachisuga T, Kawarabayashi T. The blood flow characteristics in borderline ovarian tumors based on both color Doppler ultrasound and histopathological analyses. Gynecol Oncol. 1998;70(3):351\u20137.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"568_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1067\/mob.2000.105940","volume":"183","author":"WH Gotlieb","year":"2000","unstructured":"Gotlieb WH, Soriano D, Achiron R, Zalel Y, Davidson B, Kopolovic J, et al. CA 125 measurement and ultrasonography in borderline tumors of the ovary. Am J Obstet Gynecol. 2000;183(3):541\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"568_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/jcu.10028","volume":"30","author":"MA Pascual","year":"2002","unstructured":"Pascual MA, Tresserra F, Grases PJ, Labastida R, Dexeus S. Borderline cystic tumors of the ovary: gray-scale and color Doppler sonographic findings. J Clin Ultrasound. 2002;30(2):76\u201382.","journal-title":"J Clin Ultrasound"},{"issue":"1","key":"568_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/uog.1823","volume":"25","author":"C Exacoustos","year":"2005","unstructured":"Exacoustos C, Romanini ME, Rinaldo D, Amoroso C, Szabolcs B, Zupi E, et al. Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol. 2005;25(1):50\u20139.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"568_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13244-015-0455-4","volume":"7","author":"PV Foti","year":"2016","unstructured":"Foti PV, Attina G, Spadola S, Caltabiano R, Farina R, Palmucci S, et al. MR imaging of ovarian masses: classification and differential diagnosis. Insights Imaging. 2016;7(1):21\u201341.","journal-title":"Insights Imaging"},{"issue":"1","key":"568_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000475817","volume":"83","author":"T Song","year":"2018","unstructured":"Song T, Lee DH, Jung YW, Yun BS, Seong SJ, Choi CH, et al. Elevated preoperative CA125 or CA19-9 in borderline ovarian tumors: could it be suggestive of advanced stage or a poor prognosis? Gynecol Obstet Investig. 2018;83(1):45\u201351.","journal-title":"Gynecol Obstet Investig"},{"key":"568_CR15","first-page":"403","volume":"8","author":"A Abascal-Saiz","year":"2014","unstructured":"Abascal-Saiz A, Sotillo-Mallo L, de Santiago J, Zapardiel I. Management of borderline ovarian tumours: a comprehensive review of the literature. Ecancermedicalscience. 2014;8:403.","journal-title":"Ecancermedicalscience."},{"issue":"6","key":"568_CR16","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00404-012-2453-9","volume":"286","author":"P Sobiczewski","year":"2012","unstructured":"Sobiczewski P, Danska-Bidzinska A, Rzepka J, Kupryjanczyk J, Gujski M, Bidzinski M, et al. Evaluation of selected ultrasonographic parameters and marker levels in the preoperative differentiation of borderline ovarian tumors and ovarian cancers. Arch Gynecol Obstet. 2012;286(6):1513\u20139.","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"568_CR17","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3109\/09513590.2011.633663","volume":"28","author":"I Alanbay","year":"2012","unstructured":"Alanbay I, Akturk E, Coksuer H, Ercan M, Karasahin E, Dede M, et al. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor. Gynecol Endocrinol. 2012;28(6):478\u201382.","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"568_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13048-017-0351-2","volume":"10","author":"SK Dora","year":"2017","unstructured":"Dora SK, Dandapat AB, Pande B, Hota JP. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass. J Ovarian Res. 2017;10(1):55.","journal-title":"J Ovarian Res"},{"issue":"2 Pt 1","key":"568_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/AOG.0b013e318195ad17","volume":"113","author":"P Geomini","year":"2009","unstructured":"Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol. 2009;113(2 Pt 1):384\u201394.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"568_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1055\/s-0038-1634822","volume":"30","author":"RA Hilgers","year":"1991","unstructured":"Hilgers RA. Distribution-free confidence bounds for ROC curves. Methods Inf Med. 1991;30(2):96\u2013101.","journal-title":"Methods Inf Med"},{"issue":"3","key":"568_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837\u201345.","journal-title":"Biometrics."},{"issue":"10","key":"568_CR22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","volume":"97","author":"I Jacobs","year":"1990","unstructured":"Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97(10):922\u20139.","journal-title":"Br J Obstet Gynaecol"},{"issue":"8","key":"568_CR23","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1471-0528.1996.tb09882.x","volume":"103","author":"S Tingulstad","year":"1996","unstructured":"Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol. 1996;103(8):826\u201331.","journal-title":"Br J Obstet Gynaecol"},{"issue":"3","key":"568_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/00006250-199903000-00028","volume":"93","author":"S Tingulstad","year":"1999","unstructured":"Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol. 1999;93(3):448\u201352.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"568_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejogrb.2009.02.048","volume":"144","author":"Y Yamamoto","year":"2009","unstructured":"Yamamoto Y, Yamada R, Oguri H, Maeda N, Fukaya T. Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol. 2009;144(2):163\u20137.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"568_CR26","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.fertnstert.2008.07.1716","volume":"92","author":"R Tinelli","year":"2009","unstructured":"Tinelli R, Malzoni M, Cosentino F, Perone C, Tinelli A, Malvasi A, et al. Feasibility, safety, and efficacy of conservative laparoscopic treatment of borderline ovarian tumors. Fertil Steril. 2009;92(2):736\u201341.","journal-title":"Fertil Steril"},{"issue":"2","key":"568_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejogrb.2010.07.024","volume":"153","author":"V Benito","year":"2010","unstructured":"Benito V, Lubrano A, Arencibia O, Medina N, Alvarez Eva E, Andujar M, et al. Serous and mucinous borderline ovarian tumors: are there real differences between these two entities? Eur J Obstet Gynecol Reprod Biol. 2010;153(2):188\u201392.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"6","key":"568_CR28","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/uog.2607","volume":"26","author":"E Fruscella","year":"2005","unstructured":"Fruscella E, Testa AC, Ferrandina G, De Smet F, Van Holsbeke C, Scambia G, et al. Ultrasound features of different histopathological subtypes of borderline ovarian tumors. Ultrasound Obstet Gynecol. 2005;26(6):644\u201350.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"568_CR29","first-page":"25","volume":"33","author":"I Alanbay","year":"2012","unstructured":"Alanbay I, Akt\u00fcrk E, Coksuer H, Ercan CM, Kara\u015fahin E, Dede M, et al. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors. Eur J Gynaecol Oncol. 2012;33(1):25\u201330.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"3","key":"568_CR30","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/AOG.0b013e31821477db","volume":"117","author":"American College of Obstetricians and Gynecologists Committee on gynecologic practice","year":"2011","unstructured":"American College of Obstetricians and Gynecologists Committee on gynecologic practice. Committee opinion no. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol. 2011;117(3):742\u20136.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"568_CR31","doi-asserted-by":"publisher","first-page":"d2073","DOI":"10.1136\/bmj.d2073","volume":"342","author":"C Redman","year":"2011","unstructured":"Redman C, Duffy S, Bromham N, Francis K. Guideline development group. Recognition and initial management of ovarian cancer: summary of NICE guidance. BMJ. 2011;342(1):d2073.","journal-title":"BMJ."},{"issue":"1","key":"568_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1525-1438.2006.00284.x","volume":"16","author":"M Dede","year":"2006","unstructured":"Dede M, Gungor S, Yenen MC, Alanbay I, Duru NK, Hasimi A. CA 19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer. 2006;16(1):189\u201393.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"568_CR33","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1756-185X.2011.01671.x","volume":"15","author":"S Bergamaschi","year":"2012","unstructured":"Bergamaschi S, Morato E, Bazzo M, Neves F, Fialho S, Castro G, et al. Tumor markers are elevated in patients with rheumatoid arthritis and do not indicate presence of cancer. Int J Rheum Dis. 2012;15(2):179\u201382.","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"568_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00404-008-0688-2","volume":"279","author":"U Emin","year":"2009","unstructured":"Emin U, Tayfun G, Cantekin I, Ozlem UB, Umit B, Leyla M. Tumor markers in mature cystic teratomas of the ovary. Arch Gynecol Obstet. 2009;279(2):145\u20137.","journal-title":"Arch Gynecol Obstet"},{"issue":"10","key":"568_CR35","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1177\/1933719114525274","volume":"21","author":"M Frimer","year":"2014","unstructured":"Frimer M, Seagle BL, Chudnoff S, Goldberg GL, Shahabi S. Role of elevated cancer antigen 19-9 in women with mature cystic teratoma. Reprod Sci. 2014;21(10):1307\u201311.","journal-title":"Reprod Sci"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0568-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-019-0568-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0568-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T19:12:25Z","timestamp":1600110745000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0568-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,16]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["568"],"URL":"https:\/\/doi.org\/10.1186\/s13048-019-0568-3","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,16]]},"assertion":[{"value":"24 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of Second Affiliated Hospital of Harbin Medical University. Patients who participated in this research had complete clinical data. Signed informed consents were obtained from the patients or the guardians.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}